Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | DRD2 | P14416 | 1/20 | 0.50 |
| ▸ | DRD4 | P21917 | 1/20 | 0.50 |
| ▸ | DRD3 | P35462 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | CRHBP | P24387 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.47 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | CES2 | O00748 | 2/20 | 0.46 |
| ▸ | CES1 | P23141 | 2/20 | 0.46 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL357343 | 0.92 | HSPB1 (0.52) | ALDH1A1LMNAHTTMEN1KMT2A | |
| SCHEMBL28100898 | 0.86 | POLB (0.60) | ALDH1A1LMNAMEN1KMT2AL3MBTL1 | |
| SCHEMBL28195682 | 0.84 | ALDH1A1 (0.52) | ALDH1A1LMNADRD2DRD4DRD3 | |
| SCHEMBL5712600 | 0.82 | HPGD (0.45) | ALDH1A1LMNAHTTMEN1KMT2A | |
| SCHEMBL27988874 | 0.82 | ALDH1A1 (0.50) | ALDH1A1LMNADRD2DRD4DRD3 | |
| SCHEMBL13805761 | 0.82 | LTA4H (0.43) | L3MBTL1CA1CA2CA9SRD5A2 | |
| SCHEMBL457863 | 0.80 | HSPB1 (0.68) | ALDH1A1LMNADRD2DRD4DRD3 | |
| SCHEMBL18476534 | 0.80 | ALOX5 (0.47) | ALDH1A1LMNAHTTMEN1KMT2A | |
| SCHEMBL23844032 | 0.80 | ALDH1A1 (0.43) | ALDH1A1LMNAHTTMEN1KMT2A | |
| SCHEMBL29790853 | 0.79 | LTA4H (0.45) | L3MBTL1TLR9CES2CES1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12030903-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2024-07-09 | — | — | US | disclosed |
| US-11767337-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-20230295201-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20210292348-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2021-09-23 | — | — | US | disclosed |
| US-20210284670-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2021-09-16 | — | — | US | disclosed |
| US-10717758-B2 | D-amino acid compounds for liver disease | IDENIX PHARMACEUTICALS LLC (US) | 2020-07-21 | — | — | US | disclosed |
| US-20180162898-A1 | 4'-OR NUCLEOSIDES FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS LLC (US) | 2018-06-14 | — | — | US | disclosed |
| EP-2609923-B1 | PROCESS FOR THE CRYSTALLISATION OF (S)-ISOPROPYL 2-(((S)-(PERFLUOROPHENOXY)(PHENOXY)PHOSPHORYL)AMINO)PROPANOATE | GILEAD PHARMASSET LLC (US) | 2017-05-24 | — | — | EP | disclosed |
| WO-2017024255-A1 | NICOTINAMIDE MONONUCLEOTIDE DERIVATIVES AND THEIR USES | METROBIOTECH, LLC (US) | 2017-02-09 | — | — | WO | disclosed |
| EP-2480552-B1 | 2' -FLUORO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES INC (US) | 2016-11-09 | — | — | EP | disclosed |
| US-20160002281-A1 | D-AMINO ACID COMPOUNDS FOR LIVER DISEASE | UNIVERSITE DE MONTPELLIER (FR) | 2016-01-07 | — | — | US | disclosed |
| WO-2015095419-A1 | 4'-OR NUCLEOSIDES FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS, INC. (US) | 2015-06-25 | — | — | WO | disclosed |
| US-20140140952-A1 | D-Alanine Ester of Sp-Nucleoside Analog | IDENIX PHARMACEUTICALS LLC | 2014-05-22 | — | — | US | disclosed |
| US-20120009147-A1 | 2'-FLUORO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2012-01-12 | — | — | US | disclosed |
| WO-2011123668-A2 | STEREOSELECTIVE SYNTHESIS OF PHOSPHORUS CONTAINING ACTIVES | PHARMASSET, INC. (US) | 2011-10-06 | — | — | WO | disclosed |
| WO-2011123645-A2 | NUCLEOSIDE PHOSPHORAMIDATES | PHARMASSET, INC. (US) | 2011-10-06 | — | — | WO | disclosed |
| US-7291478-B1 | Rapid screening and analysis of present and potential nerve agents and their degradation products | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 2007-11-06 | — | — | US | disclosed |
| US-5962291-A | MONOCLONAL ANTIBODY CAPABLE OF HYDROLYZING A SUBSTRATE; HAS TWO BINDING SITES: ONE FOR FREE METAL ION, ONE FOR SUBSTRATE | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 1999-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295201-A1 | ANTIVIRAL COMPOUNDS | MAVS, HAVCR2, ZC3HAV1 | ALDH1A1 1459/4885LMNA 3047/4885DRD2 2140/4885 |
| US-20140140952-A1 | D-Alanine Ester of Sp-Nucleoside Analog | PNP, DNPEP, ANPEP | ALDH1A1 753/4885LMNA 920/4885DRD2 2989/4885 |
| US-10717758-B2 | D-amino acid compounds for liver disease | AADAT, BCAT1, BCAT2 | ALDH1A1 727/4885LMNA 1857/4885DRD2 852/4885 |
| US-20120009147-A1 | 2'-FLUORO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | PNP, NSUN2, CDA | ALDH1A1 1783/4885LMNA 3489/4885DRD2 2123/4885 |
| US-12030903-B2 | Antiviral compounds | EIF2AK2, MAVS, DUT | ALDH1A1 1761/4885LMNA 3657/4885DRD2 2875/4885 |
| US-20210284670-A1 | ANTIVIRAL COMPOUNDS | MAVS, HAVCR2, ZC3HAV1 | ALDH1A1 1459/4885LMNA 3047/4885DRD2 2140/4885 |
| US-11767337-B2 | Antiviral compounds | MAVS, HAVCR2, ZC3HAV1 | ALDH1A1 1459/4885LMNA 3047/4885DRD2 2140/4885 |
| US-20210292348-A1 | ANTIVIRAL COMPOUNDS | EIF2AK2, MAVS, DUT | ALDH1A1 1761/4885LMNA 3657/4885DRD2 2875/4885 |
| US-20160002281-A1 | D-AMINO ACID COMPOUNDS FOR LIVER DISEASE | AADAT, BCAT1, BCAT2 | ALDH1A1 727/4885LMNA 1857/4885DRD2 852/4885 |
| US-20180162898-A1 | 4'-OR NUCLEOSIDES FOR THE TREATMENT OF HCV | NSUN2, NSUN3, ZC3HAV1 | ALDH1A1 483/4885LMNA 2887/4885DRD2 1788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.